{"filing":{"accession_number":"0000950103-26-008321","cik":"0001771910","ticker":"ADCT","company_name":"ADC Therapeutics SA","form":"8-K","filing_date":"2026-06-02","report_date":null,"primary_document":"dp247757_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1771910/000095010326008321/dp247757_8k.htm"},"events":[{"id":7360,"run_id":6465,"accession_number":"0000950103-26-008321","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a classic Item 5.07 disclosure of shareholder vote results from ADC Therapeutics' 2026 annual general meeting held on June 1, 2026. The filing presents detailed voting tallies for 12 proposals, including director reelections, compensation approvals, auditor reelection, and amendments to the articles of association. All proposals were approved. This is material as it documents shareholder approval of key governance matters, executive compensation, and capital structure amendments.","company_name":"ADC Therapeutics SA","ticker":"ADCT","filing_date":"2026-06-02","form":"8-K","submitted_at":null,"items":[{"id":3437,"accession_number":"0000950103-26-008321","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder vote results from ADC Therapeutics' 2026 annual general meeting held on June 1, 2026. The filing presents detailed voting tallies for 12 proposals, including director reelections, compensation approvals, auditor reelection, and amendments to the articles of association. All proposals were approved. This is material as it documents shareholder approval of key governance matters, executive compensation, and capital structure amendments.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:09:00.911190+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3437,"accession_number":"0000950103-26-008321","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder vote results from ADC Therapeutics' 2026 annual general meeting held on June 1, 2026. The filing presents detailed voting tallies for 12 proposals, including director reelections, compensation approvals, auditor reelection, and amendments to the articles of association. All proposals were approved. This is material as it documents shareholder approval of key governance matters, executive compensation, and capital structure amendments.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:09:00.911190+00:00","company_name":"ADC Therapeutics SA","ticker":"ADCT","filing_date":"2026-06-02"}]}